Dasatinib resensitizes BRAF/MEK inhibitor efficacy in patient-derived xenografts from patients with progression on BRAF/MEK inhibitor treatment

Summary: Although BRAF/MEK inhibitor (BRAFi/MEKi) therapy initially shows high efficacy in patients with BRAFV600 E/K cutaneous melanoma, resistance develops in over 75% of cases. We tested robustness of the umbrella trial strategy in this population by analyzing relationships between genomic status...

Descrición completa

Detalles Bibliográficos

Principais autores:	Vito W. Rebecca, Min Xiao, Andrew Kossenkov, Tetiana Godok, Gregory Schuyler Brown, Dylan Fingerman, Gretchen M. Alicea, Meihan Wei, Hongkai Ji, Marie Portuallo, Jeremy Bravo, Vissy Elad, Yeqing Chen, Eneda Toska, Mitchell E. Fane, Kasey L. Couts, Jessie Villanueva, Katherine Nathanson, Keerthana M. Arun, Govind Warrier, Xiangfan Yin, Jianyi Ding, Qin Liu, Yogesh Goyal, Y. N. Vashisht Gopal, Michael A. Davies, Meenhard Herlyn
Formato:	Artigo
Idioma:	Inglês
Publicado:	Elsevier 2026-02-01
Series:	iScience
Assuntos:	Cancer Therapeutics
Acceso en liña:	http://www.sciencedirect.com/science/article/pii/S2589004226000441
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!